These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 15723969)

  • 1. Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus.
    Rizzoni D; Porteri E; De Ciuceis C; Sleiman I; Rodella L; Rezzani R; Paiardi S; Bianchi R; Ruggeri G; Boari GE; Muiesan ML; Salvetti M; Zani F; Miclini M; Rosei EA
    Hypertension; 2005 Apr; 45(4):659-65. PubMed ID: 15723969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
    Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
    J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
    Rizzoni D; Porteri E; Bettoni G; Piccoli A; Castellano M; Muiesan ML; Pasini G; Guelfi D; Rosei EA
    J Cardiovasc Pharmacol; 1998 Nov; 32(5):798-806. PubMed ID: 9821855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.
    De Ciuceis C; Savoia C; Arrabito E; Porteri E; Mazza M; Rossini C; Duse S; Semeraro F; Agabiti Rosei C; Alonzo A; Sada L; La Boria E; Sarkar A; Petroboni B; Mercantini P; Volpe M; Rizzoni D; Agabiti Rosei E
    Hypertension; 2014 Oct; 64(4):717-24. PubMed ID: 24980672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
    Ishiguro K; Hayashi K; Sasamura H; Sakamaki Y; Itoh H
    Hypertension; 2009 Jan; 53(1):83-9. PubMed ID: 19047581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG; Serbul VM; Ageev FT
    Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K; Kahan T; Dahl M
    Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril.
    Ciulla MM; Paliotti R; Esposito A; Cuspidi C; Muiesan ML; Rosei EA; Magrini F; Zanchetti A
    J Hypertens; 2009 Mar; 27(3):626-32. PubMed ID: 19262230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in African-American patients with hypertension.
    Papademetriou V; Narayan P; Kokkinos P
    J Clin Hypertens (Greenwich); 2004 Jun; 6(6):310-4. PubMed ID: 15187493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan cilexetil and enalapril are of equivalent efficacy in patients with mild to moderate hypertension.
    Zanchetti A; Omboni S; Di Biagio C
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S57-9. PubMed ID: 9331009
    [No Abstract]   [Full Text] [Related]  

  • 12. Antihypertensive effects of candesartan cilexetil, enalapril and placebo.
    Franke H
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S61-2. PubMed ID: 9331010
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.
    Hasvold LP; Bodegård J; Thuresson M; Stålhammar J; Hammar N; Sundström J; Russell D; Kjeldsen SE
    J Hum Hypertens; 2014 Nov; 28(11):663-9. PubMed ID: 25211055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
    Savoia C; Touyz RM; Volpe M; Schiffrin EL
    Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model.
    Ledingham JM; Laverty R
    Clin Exp Pharmacol Physiol; 2005; 32(1-2):76-85. PubMed ID: 15730439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus.
    Malik RA; Schofield IJ; Izzard A; Austin C; Bermann G; Heagerty AM
    Hypertension; 2005 Feb; 45(2):264-9. PubMed ID: 15630048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats.
    Sharifi AM; Li JS; Endemann D; Schiffrin EL
    J Hypertens; 1998 Apr; 16(4):457-66. PubMed ID: 9797191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P; Reismann J; Pohlmeyer H; Düsing R
    Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the angiotensin receptor blocker candesartan on arterial stiffness and markers of extracellular matrix metabolism in patients with essential hypertension.
    Sasamura H; Kitamura Y; Nakamura M; Ryuzaki M; Saruta T
    Clin Exp Hypertens; 2006 Jul; 28(5):511-20. PubMed ID: 16820347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
    Schiffrin EL; Park JB; Pu Q
    J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.